Lower dose of ciprofloxacin is adequate for the treatment of Neisseria gonorrhoeae in KwaZulu Natal, South Africa

International Journal of Antimicrobial Agents

Volumn 20, Issue 4, 2002, Pages 248-252

  Moodley, Prashini ^a   Pillay, Chinsamy ^a   Nzimande, Gladys ^a   Coovadia, Yacoob M ^a   Sturm, A Willem ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Ciprofloxacin; Neisseria gonorrhoeae; Resistance

Indexed keywords

CIPROFLOXACIN; DOXYCYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DRUG EFFECT; DRUG RESPONSE; GONOCOCCAL URETHRITIS; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; PRIORITY JOURNAL;

EID: 0036776081     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00195-4     Document Type: Article

References (27)

1. Centres for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR Morbid. Mortal. Weekly Rept. 42:1993;57-59.
2. World Health Organisation programme for sexually transmitted diseases. Global programme on AIDS. Recommendations for the management of sexually transmitted diseases 1994. Geneva: WHO/GPA/TEM/94.
3. Tapsall J.W., Schultz T.R., Lovett R., Munro R. Failure of 500 mg ciprofloxacin therapy in male urethral gonorrhoea. Med. J. Aust. 156:1992;143.
4. Clendennen T.E., Echeverria P., Saengeur S., Kees E.S., Boslego J.W., Wignall F.S. Antibiotic susceptibility survey of Neisseria gonorrhoeae in Thailand. Antimicrob. Agents Chemother. 36:1992;1682-1687.
5. Tapsall J.W., Limnios E.A., Thacker C., et al. High level quinolone resistance in Neisseria gonorrhoeae: a report of two cases. Sex. Trans. Dis. 22:1995;310-311.
6. Ringuette L., Trudeau T., Turcotte T., et al. Emergence of Neisseria gonorrhoeae strains with decreased susceptibility to ciprofloxacin - Quebec, 1994-1995. Can. Commun. Dis. Rep. 22:1996;121-124.
7. Tapsall J.W., Philips E.A., Schultz T.R., Thacker C. Quinolone resistant Neisseria gonorrhoeae isolated in Sydney, Australia, 1991-1995. Sex. Trans. Dis. 23:1996;425-428.
8. Gransden W.R., Warren C.A., Philips I., Hodges M., Barlow D. Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin. Lancet. 335:1990;1951.
9. Gransden W.R., Warren C.A., Philips I. 4-Quinolone-resistant Neisseria gonorrhoeae in the United Kingdom. J. Med. Microbiol. 34:1991;23-27.
10. Centres for Disease Control and Prevention. Fluoroquinolone resistance in Neisseria gonorrhoeae - Colorado and Washington, 1995. MMWR Morbid. Mortal. Weekly Rept. 20:1995;761-764.
11. Ng P.P., Chan R.K., Ling A.E. Gonorrhoea treatment failure and ciprofloxacin resistance. Int. J. STD AIDS. 9:1998;323-325.
12. Rahman M., Alam A., Nessa K., et al. Treatment failure with the use of ciprofloxacin for gonorrhoea correlates with the prevalence of fluoroquinolone-resistant Neisseria gonorrhoeae strains in Bangladesh. Clin. Infect. Dis. 32:2001;884-889.
13. Jones R.N., Gavan T.L., Thornsberry C., et al. Standardisation of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretative criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin and tetracycline. J. Clin. Microbiol. 27:1989;2758-2766.
14. Moodley P., Sturm A.W. Ciprofloxacin resistance in Neisseria gonorrhoeae. Lancet. 357:2001;1295-1296.
15. National Committee for Clinical Laboratory Standards, 1997. Standard methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically - 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Villanova, PA.
16. Moodley P., Pillay C., Goga R., Kharsany A.B.M., Sturm A.W. Evolution in the trends of antimicrobial resistance in Neisseria gonorrhoea isolates in Durban over a 5-year period: impact of the introduction of syndromic management. J. Antimicrob. Chemother. 48:2001;853-859.
17. Blaser J., Stone B.B., Groner M.C., Zinner S.H. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1987;1054-1060.
18. Bowker K.E., Wootton M., Rogers C.A., Lewis R., Holt H.A., MacGowan A.P. Comparison of in vitro pharmacodynamics of once and twice daily ciprofloxacin. J. Antimicrob. Chemother. 44:1999;661-667.
19. Hooper D.C. Quinolones. Mandell G.L., Bennet J.E., Dolin R., Mandell, Douglas and Bennet's principles and practice of infectious diseases. 4th ed. 1995;Churchill Livingstone.
20. Jaffe H.W., Schroeter A.L., Reynolds G.H., Zaidi A.A., Martin J.E. Jr, Thayer J.D. Pharmacokinetic determinants of penicillin cure of gonococcal urethritis. Antimicrob. Agents Chemother. 15:1979;587-591.
21. Knapp J.S., Hale J.A., Wintersheid K., Neal S.W., Whittington W.L. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin and norfloxacin. Antimicrob. Agents Chemother. 39:1995;2442-2445.
22. Knapp J.S., Fox K.K., Trees D.L., Whittington W.L. Fluoroquinolone resistance in Neisseria gonorrhoeae. Emerg. Infect. Dis. 3:1997;33-39.
23. Baquero F., Negri M.C., Morosini M.I., Blazquez J. Antibiotic-selective environments. Clin. Infect. Dis. 27:(Suppl. 1):1998;S5-S11.
24. Lipsitch M. Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. Clin. Infect. Dis. 32:2001;1044-1054.
25. Tanaka M., Sakuma S., Takahashi K., et al. Analysis of quinolone resistance mechanisms in Neisseria gonorrhoeae isolates in vitro. Sex. Transm. Dis. 74:1998;59-62.
26. Tanaka M., Takahashi K., Saika T., et al. Development of fluroquinolone resistance and mutations involving GyrA and ParC proteins among Neisseria gonorrhoeae isolates in Japan. J. Urol. 159:1998;2215-2219.
27. Trees D.L., Sandul A.L., Peto-Mesola V., et al. Alterations within the quinolone resistance-determining regions of GyrA and ParC of Neisseria gonorrhoeae isolated in the Far East and the United States. Int. J. Antimicrob. Agents. 12:1999;325-332.